{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:00:55Z","timestamp":1770224455750,"version":"3.49.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T00:00:00Z","timestamp":1538092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Left ventricular myocardial fibrosis in patients with aortic stenosis (AS) confers worse prognosis. Plasma osteoprotegerin (OPG), a cytokine from the TNF receptor family, correlates with the degree of valve calcification in AS, reflecting the activity of the tissue RANKL\/RANK\/OPG (receptor activator of nuclear factor \u03ba\u0392 ligand\/RANK\/osteoprotegerin) axis, and is associated with poorer outcomes in AS. Its association with myocardial fibrosis is unknown. We hypothesised that OPG levels would reflect the extent of myocardial fibrosis in AS. We included 110 consecutive patients with AS who had undergone late-gadolinium contrast enhanced cardiovascular magnetic resonance (LGE-CMR). Patients were characterised according to pattern of fibrosis (no fibrosis, midwall fibrosis, or chronic myocardial infarction fibrosis). Serum OPG was measured with ELISA and compared between groups defined by valve stenosis severity. Some 36 patients had no fibrosis, 38 had midwall fibrosis, and 36 had chronic infarction. Patients with midwall fibrosis did not have higher levels of OPG compared to those without fibrosis (6.78 vs. 5.25 pmol\/L, p\u2009=\u20090.12). There was no difference between those with midwall or chronic myocardial infarction fibrosis (6.78 vs. 6.97 pmol\/L, p\u2009=\u20090.27). However, OPG levels in patients with chronic myocardial infarction fibrosis were significantly higher than those without fibrosis (p\u2009=\u20090.005).<\/jats:p>","DOI":"10.1038\/s41598-018-32738-y","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T14:39:11Z","timestamp":1537799951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Osteoprotegerin and Myocardial Fibrosis in Patients with Aortic Stenosis"],"prefix":"10.1038","volume":"8","author":[{"given":"Brodie L.","family":"Loudon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleana","family":"Ntatsaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-1217","authenticated-orcid":false,"given":"Simon","family":"Newsome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrit","family":"Lota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamir","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamir","family":"Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subothini","family":"Selvendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willis","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominque","family":"Auger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E.","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dudley J.","family":"Pennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassilios S.","family":"Vassiliou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay K.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,28]]},"reference":[{"key":"32738_CR1","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1161\/CIRCULATIONAHA.104.486738","volume":"111","author":"RV Freeman","year":"2005","unstructured":"Freeman, R. V. & Otto, C. M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111, 3316\u20133326 (2005).","journal-title":"Circulation"},{"key":"32738_CR2","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1161\/01.ATV.0000227513.13697.ac","volume":"26","author":"KD O\u2019Brien","year":"2006","unstructured":"O\u2019Brien, K. D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26, 1721\u20131728 (2006).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"32738_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","volume":"70","author":"RA Nishimura","year":"2017","unstructured":"Nishimura, R. A. et al. 2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70, 252\u2013289 (2017).","journal-title":"J Am Coll Cardiol"},{"key":"32738_CR4","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner, H. et al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38, 2739\u20132791 (2017).","journal-title":"Eur Heart J"},{"key":"32738_CR5","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/01.CIR.0000051865.66123.B7","volume":"107","author":"S Hein","year":"2003","unstructured":"Hein, S. et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107, 984\u2013991 (2003).","journal-title":"Circulation"},{"key":"32738_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1161\/01.CIR.0000162463.61626.3B","volume":"111","author":"SV Babu-Narayan","year":"2005","unstructured":"Babu-Narayan, S. V. et al. Late gadolinium enhancement cardiovascular magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery for transposition of the great arteries. Circulation 111, 2091\u20132098 (2005).","journal-title":"Circulation"},{"key":"32738_CR7","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2017.01.034","volume":"69","author":"VS Vassiliou","year":"2017","unstructured":"Vassiliou, V. S. et al. Midwall Fibrosis and 5-Year Outcome in Moderate and Severe Aortic Stenosis. J Am Coll Cardiol 69, 1755\u20131756 (2017).","journal-title":"J Am Coll Cardiol"},{"key":"32738_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","volume":"95","author":"P Collin-Osdoby","year":"2004","unstructured":"Collin-Osdoby, P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95, 1046\u20131057 (2004).","journal-title":"Circ Res"},{"key":"32738_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","volume":"36","author":"JJ Kaden","year":"2004","unstructured":"Kaden, J. J. et al. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36, 57\u201366 (2004).","journal-title":"J Mol Cell Cardiol"},{"key":"32738_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1359-6101(03)00027-3","volume":"14","author":"MC Walsh","year":"2003","unstructured":"Walsh, M. C. & Choi, Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 14, 251\u2013263 (2003).","journal-title":"Cytokine Growth Factor Rev"},{"key":"32738_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315\u2013323 (1999).","journal-title":"Nature"},{"key":"32738_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/hrt.2005.075903","volume":"92","author":"R Shetty","year":"2006","unstructured":"Shetty, R. et al. Expression of bone-regulatory proteins in human valve allografts. Heart 92, 1303\u20131308 (2006).","journal-title":"Heart"},{"key":"32738_CR13","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/j.humpath.2008.04.015","volume":"39","author":"V Pohjolainen","year":"2008","unstructured":"Pohjolainen, V. et al. Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol 39, 1695\u20131701 (2008).","journal-title":"Hum Pathol"},{"key":"32738_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1161\/CIRCRESAHA.108.189001","volume":"104","author":"S Panizo","year":"2009","unstructured":"Panizo, S. et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104, 1041\u20131048 (2009).","journal-title":"Circ Res"},{"key":"32738_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","volume":"12","author":"N Bucay","year":"1998","unstructured":"Bucay, N. et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12, 1260\u20131268 (1998).","journal-title":"Genes Dev"},{"key":"32738_CR16","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1161\/hq1201.100229","volume":"21","author":"CR Dhore","year":"2001","unstructured":"Dhore, C. R. et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21, 1998\u20132003 (2001).","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"32738_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1084\/jem.192.4.463","volume":"192","author":"H Min","year":"2000","unstructured":"Min, H. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192, 463\u2013474 (2000).","journal-title":"J Exp Med"},{"key":"32738_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2840-12-11","volume":"12","author":"A Aoki","year":"2013","unstructured":"Aoki, A. et al. Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes. Cardiovasc Diabetol 12, 11 (2013).","journal-title":"Cardiovasc Diabetol"},{"key":"32738_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ahj.2010.05.015","volume":"160","author":"R Roysland","year":"2010","unstructured":"Roysland, R. et al. Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial. Am Heart J 160, 286\u2013293 (2010).","journal-title":"Am Heart J"},{"key":"32738_CR20","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCHEARTFAILURE.110.957332","volume":"4","author":"T Ueland","year":"2011","unstructured":"Ueland, T. et al. Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail 4, 145\u2013152 (2011).","journal-title":"Circ Heart Fail"},{"key":"32738_CR21","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1161\/01.CIR.0000165119.62099.14","volume":"111","author":"T Ueland","year":"2005","unstructured":"Ueland, T. et al. Dysregulated osteoprotegerin\/RANK ligand\/RANK axis in clinical and experimental heart failure. Circulation 111, 2461\u20132468 (2005).","journal-title":"Circulation"},{"key":"32738_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/j.1365-2796.2011.02393.x","volume":"270","author":"T Ueland","year":"2011","unstructured":"Ueland, T. et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med 270, 452\u2013460 (2011).","journal-title":"J Intern Med"},{"key":"32738_CR23","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/j.amjcard.2013.06.015","volume":"112","author":"JS Dahl","year":"2013","unstructured":"Dahl, J. S. et al. Relation of osteoprotegerin in severe aortic valve stenosis to postoperative outcome and left ventricular function. Am J Cardiol 112, 1433\u20131438 (2013).","journal-title":"Am J Cardiol"},{"key":"32738_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ejheart.2006.10.015","volume":"9","author":"S Helske","year":"2007","unstructured":"Helske, S. et al. Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 9, 357\u2013363 (2007).","journal-title":"Eur J Heart Fail"},{"key":"32738_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.echo.2006.11.020","volume":"20","author":"SH Poulsen","year":"2007","unstructured":"Poulsen, S. H., Sogaard, P., Nielsen-Kudsk, J. E. & Egeblad, H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. J Am Soc Echocardiogr 20, 877\u2013884 (2007).","journal-title":"J Am Soc Echocardiogr"},{"key":"32738_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1161\/CIRCULATIONAHA.108.847772","volume":"120","author":"F Weidemann","year":"2009","unstructured":"Weidemann, F. et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 120, 577\u2013584 (2009).","journal-title":"Circulation"},{"key":"32738_CR27","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1093\/eurheartj\/ehr084","volume":"32","author":"AC Ng","year":"2011","unstructured":"Ng, A. C. et al. Alterations in multidirectional myocardial functions in patients with aortic stenosis and preserved ejection fraction: a two-dimensional speckle tracking analysis. Eur Heart J 32, 1542\u20131550 (2011).","journal-title":"Eur Heart J"},{"key":"32738_CR28","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jacc.2011.03.064","volume":"58","author":"MR Dweck","year":"2011","unstructured":"Dweck, M. R. et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 58, 1271\u20131279 (2011).","journal-title":"J Am Coll Cardiol"},{"key":"32738_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jacc.2014.02.612","volume":"64","author":"G Barone-Rochette","year":"2014","unstructured":"Barone-Rochette, G. et al. Prognostic significance of LGE by CMR in aortic stenosis patients undergoing valve replacement. J Am Coll Cardiol 64, 144\u2013154 (2014).","journal-title":"J Am Coll Cardiol"},{"key":"32738_CR30","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jcmg.2016.10.007","volume":"10","author":"CWL Chin","year":"2017","unstructured":"Chin, C. W. L. et al. Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis. J Am Coll Cardiol Img 10, 1320\u20131333 (2017).","journal-title":"J Am Coll Cardiol Img"},{"key":"32738_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S0008-6363(98)00305-8","volume":"41","author":"A Nicoletti","year":"1999","unstructured":"Nicoletti, A. & Michel, J. B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 41, 532\u2013543 (1999).","journal-title":"Cardiovasc Res"},{"key":"32738_CR32","first-page":"144","volume":"13","author":"N Saidenberg Kermanac\u2019h","year":"2002","unstructured":"Saidenberg Kermanac\u2019h, N., Bessis, N., Cohen-Solal, M., De Vernejoul, M. C. & Boissier, M. C. Osteoprotegerin and inflammation. Eur Cytokine Netw 13, 144\u2013153 (2002).","journal-title":"Eur Cytokine Netw"},{"key":"32738_CR33","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.yexmp.2009.06.001","volume":"87","author":"W Feng","year":"2009","unstructured":"Feng, W. et al. IL-17 induces myocardial fibrosis and enhances RANKL\/OPG and MMP\/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 87, 212\u2013218 (2009).","journal-title":"Exp Mol Pathol"},{"key":"32738_CR34","doi-asserted-by":"publisher","first-page":"e0181077","DOI":"10.1371\/journal.pone.0181077","volume":"12","author":"VS Vassiliou","year":"2017","unstructured":"Vassiliou, V. S. et al. Lipoprotein(a) in patients with aortic stenosis: Insights from cardiovascular magnetic resonance. PLoS One 12, e0181077 (2017).","journal-title":"PLoS One"},{"key":"32738_CR35","doi-asserted-by":"publisher","first-page":"e0183910","DOI":"10.1371\/journal.pone.0183910","volume":"12","author":"L Tschiderer","year":"2017","unstructured":"Tschiderer, L., Willeit, J., Schett, G., Kiechl, S. & Willeit, P. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS One 12, e0183910 (2017).","journal-title":"PLoS One"},{"key":"32738_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37, 2129\u20132200 (2016).","journal-title":"Eur Heart J"},{"key":"32738_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bcp.2006.09.007","volume":"73","author":"E Ben-Tal Cohen","year":"2007","unstructured":"Ben-Tal Cohen, E. et al. Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 73, 77\u201383 (2007).","journal-title":"Biochem Pharmacol"},{"key":"32738_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309\u2013319 (1997).","journal-title":"Cell"},{"key":"32738_CR39","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","volume":"186","author":"BR Wong","year":"1997","unstructured":"Wong, B. R. et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186, 2075\u20132080 (1997).","journal-title":"J Exp Med"},{"key":"32738_CR40","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1091\/mbc.e04-01-0059","volume":"15","author":"LB Pritzker","year":"2004","unstructured":"Pritzker, L. B., Scatena, M. & Giachelli, C. M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15, 2834\u20132841 (2004).","journal-title":"Mol Biol Cell"},{"key":"32738_CR41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.atherosclerosis.2011.05.019","volume":"218","author":"B Toffoli","year":"2011","unstructured":"Toffoli, B. et al. Osteoprotegerin promotes vascular fibrosis via a TGF-beta1 autocrine loop. Atherosclerosis 218, 61\u201368 (2011).","journal-title":"Atherosclerosis"},{"key":"32738_CR42","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.jacc.2010.03.013","volume":"55","author":"SM Venuraju","year":"2010","unstructured":"Venuraju, S. M., Yerramasu, A., Corder, R. & Lahiri, A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 55, 2049\u20132061 (2010).","journal-title":"J Am Coll Cardiol"},{"key":"32738_CR43","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1161\/01.CIR.0000143073.60937.50","volume":"110","author":"AY Chong","year":"2004","unstructured":"Chong, A. Y. et al. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 110, 1794\u20131798 (2004).","journal-title":"Circulation"},{"key":"32738_CR44","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.CIR.102.3.351","volume":"102","author":"R Varin","year":"2000","unstructured":"Varin, R. et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 102, 351\u2013356 (2000).","journal-title":"Circulation"},{"key":"32738_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1042\/CS20040255","volume":"108","author":"EJ Rhee","year":"2005","unstructured":"Rhee, E. J. et al. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond) 108, 237\u2013243 (2005).","journal-title":"Clin Sci (Lond)"},{"key":"32738_CR46","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.jacc.2004.06.076","volume":"44","author":"T Ueland","year":"2004","unstructured":"Ueland, T. et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44, 1970\u20131976 (2004).","journal-title":"J Am Coll Cardiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32738-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:55:23Z","timestamp":1671616523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["32738"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-32738-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,28]]},"assertion":[{"value":"17 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof. Pennell has received research funding from Siemens; has served as a consultant to Bayer; and is a director of and shareholder in CVIS. Dr. Prasad has received honoraria for talks from Bayer Schering. This project was supported by the Rosetrees Trust, the National Institute for Health Research (NIHR) Cardiovascular Biomedical Research Unit (CBRU) of Royal Brompton and Harefield NHS Trust and Imperial College London, and the British Heart Foundation through BHF CRTF (FS\/17\/21\/32712) and BHF CRTF (FS\/15\/29\/31492).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"14550"}}